Navigation Links
Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)

- Management to discuss third quarter financial results -

LAVAL, QC, Oct. 29 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Friday, November 7 at 8:30 a.m. (ET) to discuss its third quarter 2008 financial results. Labopharm will report its third quarter 2008 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3427 or 1-800-588-4490. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, November 14, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21287767 followed by the number sign.

A live audio webcast of the conference call will be available at Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... of telemedicine programs in communities throughout Georgia, along with affiliate organizations, Alabama Partnership ... for their regional telehealth summits for Fall 2015. , Each of the ...
(Date:10/13/2015)... FL (PRWEB) , ... October 13, 2015 , ... ... the Driveway Snow Blanket, a snow melting invention that helps people in clearing snow ... billion and will continue to grow at 3.8% per year," says Scott Cooper, CEO ...
(Date:10/13/2015)... ... October 13, 2015 , ... Breathing ... people do not breathe correctly. According to T’ai Chi (also spelled “Taiji”) and ... to breathe correctly, in concert with the 7,000 year old tradition they teach, ...
(Date:10/13/2015)... ... October 13, 2015 , ... CVS/pharmacy, the retail division ... for enrolling and serving insurance consumers who do not have a bank account, ... monthly premiums. In “Health Plan Engagement Strategies: The ABCs of Serving Consumers Who ...
(Date:10/13/2015)... Baltimore, MD (PRWEB) , ... October 13, 2015 ... ... and retailing sustainable and eco-friendly home furnishings and décor, today announced it closed ... growth equity investor. The funds will be used to support the Company’s continued ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... ROSEMONT, Ill. , Oct. 12, 2015  To ... the American Academy of Orthopaedic Surgeons (AAOS) ... increase and improve physician, caregiver and patient education; the ... pain management; and support for more effective opioid abuse ... a member of the AAOS Patient Safety Committee. "The ...
(Date:10/12/2015)... 12, 2015 --> ... the global vital signs monitoring devices market in its upcoming ... and Opportunity Assessment 2015-2025." The global vital signs monitoring devices ... 9.5% and 9.2% in terms of value and volume, respectively, ... offers major insights in detail in this report. ...
(Date:10/12/2015)... Oct. 12, 2015   Royal Philips (NYSE: ... pathology, today announced a collaboration with Genomic Health ... provider of genomic-based diagnostic tests, to leverage Philips digital ... its molecular diagnostic testing processes.    ... of patient tissue samples and plays a crucial role ...
Breaking Medicine Technology: